[Intracerebral transplantation of genetically modified cells for Parkinson's disease].
The clinical application of brain transplantation for treating Parkinson's disease (PD) is limited because it is difficult to obtain ideal donor cells. In this study, the tyrosine hydroxylase (TH) gene was introduced into NIH-3T3 cell line and the genetically modified cells reacted positively with TH antiserum and released L-dopa. These cells were implanted into the striatum of PD rats. 3,6,9,12 days after implantation, the average rate of the abnormal rotational behavior recovery was 52.6%, 68.4%, 63.2%, 44.7%, respectively. This result is considered to be potential for further clinical application.
Tang
Z
Z
Department of Neurosurgery, Huashan Hospital, Shanghai.
Ying
Q
Q
Peng
L
L
D016475:3T3 Cells; D000818:Animals; D003342:Corpus Striatum / Q000601:surgery; D016332:Fetal Tissue Transplantation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D007980:Levodopa / Q000096:biosynthesis; D051379:Mice; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism / Q000628:therapy*; D051381:Rats; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics*
D007980:Levodopa; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase